+Follow
learndaily
No personal profile
9
Follow
1
Followers
0
Topic
0
Badge
Posts
Hot
learndaily
2021-06-15
Why can't I read this report
Sorry, the original content has been removed
learndaily
2021-06-14
Good
Vaccine Stocks Slide After Novavax Shot Proves Highly Effective
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3570073702642816","uuid":"3570073702642816","gmtCreate":1622774153775,"gmtModify":1622774153775,"name":"learndaily","pinyin":"learndaily","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":9,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.06.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":187043799,"gmtCreate":1623732028111,"gmtModify":1704209865056,"author":{"id":"3570073702642816","authorId":"3570073702642816","name":"learndaily","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570073702642816","authorIdStr":"3570073702642816"},"themes":[],"htmlText":"Why can't I read this report","listText":"Why can't I read this report","text":"Why can't I read this report","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187043799","repostId":"2143787257","repostType":2,"isVote":1,"tweetType":1,"viewCount":81,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184320723,"gmtCreate":1623685202462,"gmtModify":1704208735070,"author":{"id":"3570073702642816","authorId":"3570073702642816","name":"learndaily","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570073702642816","authorIdStr":"3570073702642816"},"themes":[],"htmlText":"Good ","listText":"Good ","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/184320723","repostId":"2143738859","repostType":4,"repost":{"id":"2143738859","kind":"news","pubTimestamp":1623684317,"share":"https://ttm.financial/m/news/2143738859?lang=&edition=fundamental","pubTime":"2021-06-14 23:25","market":"us","language":"en","title":"Vaccine Stocks Slide After Novavax Shot Proves Highly Effective","url":"https://stock-news.laohu8.com/highlight/detail?id=2143738859","media":"Bloomberg","summary":"(Bloomberg) -- The world’s top makers of Covid-19 vaccines are dropping after tests of Novavax Inc.’","content":"<p>(Bloomberg) -- The world’s top makers of Covid-19 vaccines are dropping after tests of Novavax Inc.’s shots showed they were 90% effective at preventing symptoms.</p>\n<p>Stocks tied to inoculations already cleared for emergency use fell in Monday’s trading, led by Moderna Inc.’s slide of as much as 9.5%. Pfizer Inc. fell 1.6% and the drugmaker’s German partner <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> dropped 6.1%. Even the consumer giant Johnson & Johnson slipped 0.6%, slightly more than the S&P 500 index as the broader market dropped back from Friday’s record highs.</p>\n<p>Novavax itself wasn’t immune from the downdraft it created, with the stock reversing a 9.5% gain on Monday to fall about 1%. The shot’s efficacy was better than Wall Street was expecting amid the spread of more resistant variants, and that’s raising the specter of new competition. Novavax now has “a viable alternative to mRNA vaccines,” like Pfizer and BioNTech or Moderna’s shots, an analyst at Jefferies said.</p>\n<p>But with Novavax up 91% so far this year and after a more than 2,700% leap in 2020, it wasn’t enough to further bolster shares. Biotech stocks often climb ahead of highly watched catalyst, only to give back gains even after a positive update.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine Stocks Slide After Novavax Shot Proves Highly Effective</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine Stocks Slide After Novavax Shot Proves Highly Effective\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-14 23:25 GMT+8 <a href=https://finance.yahoo.com/news/vaccine-stocks-slide-novavax-shot-145617752.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- The world’s top makers of Covid-19 vaccines are dropping after tests of Novavax Inc.’s shots showed they were 90% effective at preventing symptoms.\nStocks tied to inoculations already ...</p>\n\n<a href=\"https://finance.yahoo.com/news/vaccine-stocks-slide-novavax-shot-145617752.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞","MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://finance.yahoo.com/news/vaccine-stocks-slide-novavax-shot-145617752.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143738859","content_text":"(Bloomberg) -- The world’s top makers of Covid-19 vaccines are dropping after tests of Novavax Inc.’s shots showed they were 90% effective at preventing symptoms.\nStocks tied to inoculations already cleared for emergency use fell in Monday’s trading, led by Moderna Inc.’s slide of as much as 9.5%. Pfizer Inc. fell 1.6% and the drugmaker’s German partner BioNTech SE dropped 6.1%. Even the consumer giant Johnson & Johnson slipped 0.6%, slightly more than the S&P 500 index as the broader market dropped back from Friday’s record highs.\nNovavax itself wasn’t immune from the downdraft it created, with the stock reversing a 9.5% gain on Monday to fall about 1%. The shot’s efficacy was better than Wall Street was expecting amid the spread of more resistant variants, and that’s raising the specter of new competition. Novavax now has “a viable alternative to mRNA vaccines,” like Pfizer and BioNTech or Moderna’s shots, an analyst at Jefferies said.\nBut with Novavax up 91% so far this year and after a more than 2,700% leap in 2020, it wasn’t enough to further bolster shares. Biotech stocks often climb ahead of highly watched catalyst, only to give back gains even after a positive update.","news_type":1},"isVote":1,"tweetType":1,"viewCount":141,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":184320723,"gmtCreate":1623685202462,"gmtModify":1704208735070,"author":{"id":"3570073702642816","authorId":"3570073702642816","name":"learndaily","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570073702642816","authorIdStr":"3570073702642816"},"themes":[],"htmlText":"Good ","listText":"Good ","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/184320723","repostId":"2143738859","repostType":4,"repost":{"id":"2143738859","kind":"news","pubTimestamp":1623684317,"share":"https://ttm.financial/m/news/2143738859?lang=&edition=fundamental","pubTime":"2021-06-14 23:25","market":"us","language":"en","title":"Vaccine Stocks Slide After Novavax Shot Proves Highly Effective","url":"https://stock-news.laohu8.com/highlight/detail?id=2143738859","media":"Bloomberg","summary":"(Bloomberg) -- The world’s top makers of Covid-19 vaccines are dropping after tests of Novavax Inc.’","content":"<p>(Bloomberg) -- The world’s top makers of Covid-19 vaccines are dropping after tests of Novavax Inc.’s shots showed they were 90% effective at preventing symptoms.</p>\n<p>Stocks tied to inoculations already cleared for emergency use fell in Monday’s trading, led by Moderna Inc.’s slide of as much as 9.5%. Pfizer Inc. fell 1.6% and the drugmaker’s German partner <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> dropped 6.1%. Even the consumer giant Johnson & Johnson slipped 0.6%, slightly more than the S&P 500 index as the broader market dropped back from Friday’s record highs.</p>\n<p>Novavax itself wasn’t immune from the downdraft it created, with the stock reversing a 9.5% gain on Monday to fall about 1%. The shot’s efficacy was better than Wall Street was expecting amid the spread of more resistant variants, and that’s raising the specter of new competition. Novavax now has “a viable alternative to mRNA vaccines,” like Pfizer and BioNTech or Moderna’s shots, an analyst at Jefferies said.</p>\n<p>But with Novavax up 91% so far this year and after a more than 2,700% leap in 2020, it wasn’t enough to further bolster shares. Biotech stocks often climb ahead of highly watched catalyst, only to give back gains even after a positive update.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine Stocks Slide After Novavax Shot Proves Highly Effective</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine Stocks Slide After Novavax Shot Proves Highly Effective\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-14 23:25 GMT+8 <a href=https://finance.yahoo.com/news/vaccine-stocks-slide-novavax-shot-145617752.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- The world’s top makers of Covid-19 vaccines are dropping after tests of Novavax Inc.’s shots showed they were 90% effective at preventing symptoms.\nStocks tied to inoculations already ...</p>\n\n<a href=\"https://finance.yahoo.com/news/vaccine-stocks-slide-novavax-shot-145617752.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","PFE":"辉瑞","MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://finance.yahoo.com/news/vaccine-stocks-slide-novavax-shot-145617752.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143738859","content_text":"(Bloomberg) -- The world’s top makers of Covid-19 vaccines are dropping after tests of Novavax Inc.’s shots showed they were 90% effective at preventing symptoms.\nStocks tied to inoculations already cleared for emergency use fell in Monday’s trading, led by Moderna Inc.’s slide of as much as 9.5%. Pfizer Inc. fell 1.6% and the drugmaker’s German partner BioNTech SE dropped 6.1%. Even the consumer giant Johnson & Johnson slipped 0.6%, slightly more than the S&P 500 index as the broader market dropped back from Friday’s record highs.\nNovavax itself wasn’t immune from the downdraft it created, with the stock reversing a 9.5% gain on Monday to fall about 1%. The shot’s efficacy was better than Wall Street was expecting amid the spread of more resistant variants, and that’s raising the specter of new competition. Novavax now has “a viable alternative to mRNA vaccines,” like Pfizer and BioNTech or Moderna’s shots, an analyst at Jefferies said.\nBut with Novavax up 91% so far this year and after a more than 2,700% leap in 2020, it wasn’t enough to further bolster shares. Biotech stocks often climb ahead of highly watched catalyst, only to give back gains even after a positive update.","news_type":1},"isVote":1,"tweetType":1,"viewCount":141,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187043799,"gmtCreate":1623732028111,"gmtModify":1704209865056,"author":{"id":"3570073702642816","authorId":"3570073702642816","name":"learndaily","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3570073702642816","authorIdStr":"3570073702642816"},"themes":[],"htmlText":"Why can't I read this report","listText":"Why can't I read this report","text":"Why can't I read this report","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187043799","repostId":"2143787257","repostType":2,"repost":{"id":"2143787257","kind":"news","pubTimestamp":1623674412,"share":"https://ttm.financial/m/news/2143787257?lang=&edition=fundamental","pubTime":"2021-06-14 20:40","market":"us","language":"en","title":"Kroger (KR) Queued for Q1 Earnings: Factors to Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=2143787257","media":"Zacks","summary":"The Kroger Co. KR is likely to register a decline in the top line when it reports first-quarter fisc","content":"<html><body><p><strong>The Kroger Co.</strong> KR is likely to register a decline in the top line when it reports first-quarter fiscal 2021 results on Jun 17, before the market opens. The Zacks Consensus Estimate for revenues is pegged at $39,222 million, indicating a decline of 5.6% from the prior-year reported figure.<br/><br/>Further, the bottom line of this operator of supermarket chain is expected to decrease year over year. We note that the Zacks Consensus Estimate for earnings for the quarter under review has been stable at 99 cents over the past 30 days. The figure suggests a decline from $1.22 per share reported in the year-ago period.<br/><br/>Notably, the company has a trailing four-quarter earnings surprise of 19.3%, on average. In the last reported quarter, this Cincinnati, OH-based company’s bottom line surpassed the Zacks Consensus Estimate by 17.4%.</p>\n<h3>Key Factors to Note</h3>\n<p>Kroger is likely to have faced tough year-over-year comparisons in sales, as COVID-19 benefits are lapped. Industry experts believe that lower at-home consumption activities and a drop in pantry-loading trends might have hurt the company’s first-quarter top-line performance.<br/><br/>Apart from this, stiff competition in the grocery segment remained a significant headwind. Again, costs related to additional employee payments and benefits, and investments undertaken to preserve safety and health of customers and team members amid the coronavirus crisis might have weighed on the to-be-reported quarter’s margins.<br/><br/>While aforementioned factors do raise concerns, we cannot ignore the efforts undertaken by Kroger to strengthen position not only with respect to products but also in terms of the way consumers prefer shopping. The company has been making significant investments to enhance product freshness and quality, and expand digital capabilities. Impressively, Kroger has been introducing new items under its “Our Brands” portfolio. Cumulatively, these are likely to have aided the company’s first-quarter performance.<br/><br/>The company’s “Restock Kroger” program involving investments in omni-channel platform, identifying margin-rich alternative profit streams, merchandise optimization, and lowering of expenses have been gaining traction. Realizing the need of the hour, the company has been offering a no-contact delivery option, low-contact pickup service and ship-to-home orders.</p>\n<div>\n<h3>The Kroger Co. Price, Consensus and EPS Surprise</h3>\n<p> <img height=\"264\" src=\"https://s1.yimg.com/uu/api/res/1.2/ln6SOUdg3f7yByRzXswbJw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/6f7deb163bd8795bd2b0804d55232b56\" title=\"\" width=\"570\"/> </p>\n<p>The Kroger Co. price-consensus-eps-surprise-chart | The Kroger Co. Quote</p>\n</div>\n<h3>What the Zacks Model Unveils</h3>\n<p>Our proven model does not conclusively predict a beat for Kroger this earnings season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.<br/><br/>Kroger has a Zacks Rank #3 but an Earnings ESP of 0.00%.</p>\n<h3>Stocks With Favorable Combination</h3>\n<p>Here are some companies you may want to consider as our model shows that these have the right combination of elements to post an earnings beat:</p>\n<p><strong><a href=\"https://laohu8.com/S/KBH\">KB Home</a></strong> KBH has an Earnings ESP of +1.87% and a Zacks Rank #2. You can see <strong>the complete list of today’s Zacks #1 Rank stocks here</strong>.<br/><br/><strong>General Mills</strong> GIS has an Earnings ESP of +2.06% and a Zacks Rank #3.<br/><br/><strong>Darden Restaurants </strong>DRI has an Earnings ESP of +17.46% and a Zacks Rank #3.</p>\n<h3>Bitcoin, Like the Internet Itself, Could Change Everything</h3>\n<p>Blockchain and cryptocurrency has sparked <a href=\"https://laohu8.com/S/AONE\">one</a> of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.<br/><br/>Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.<br/><br/><strong>See 3 crypto-related stocks now >></strong></p>\n<br/>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n<br/> \n<br/>\nGeneral Mills, Inc. (GIS) : Free Stock Analysis Report\n<br/> \n<br/>\nDarden Restaurants, Inc. (DRI) : Free Stock Analysis Report\n<br/> \n<br/>\nThe Kroger Co. (KR) : Free Stock Analysis Report\n<br/> \n<br/>\nKB Home (KBH) : Free Stock Analysis Report\n<br/> \n<br/>\nTo read this article on Zacks.com click here.\n<br/> \n<br/>\nZacks Investment Research</body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kroger (KR) Queued for Q1 Earnings: Factors to Consider</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKroger (KR) Queued for Q1 Earnings: Factors to Consider\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-14 20:40 GMT+8 <a href=https://finance.yahoo.com/news/kroger-kr-queued-q1-earnings-124012094.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Kroger Co. KR is likely to register a decline in the top line when it reports first-quarter fiscal 2021 results on Jun 17, before the market opens. The Zacks Consensus Estimate for revenues is ...</p>\n\n<a href=\"https://finance.yahoo.com/news/kroger-kr-queued-q1-earnings-124012094.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/Hs3ZSi1_MiuDm2Xosi2cMg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/x_9tDBRvijQEdUheNcHYcA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ce1f6029b6b998b98e4d6aeab07a59d5","relate_stocks":{"KR":"克罗格"},"source_url":"https://finance.yahoo.com/news/kroger-kr-queued-q1-earnings-124012094.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143787257","content_text":"The Kroger Co. KR is likely to register a decline in the top line when it reports first-quarter fiscal 2021 results on Jun 17, before the market opens. The Zacks Consensus Estimate for revenues is pegged at $39,222 million, indicating a decline of 5.6% from the prior-year reported figure.Further, the bottom line of this operator of supermarket chain is expected to decrease year over year. We note that the Zacks Consensus Estimate for earnings for the quarter under review has been stable at 99 cents over the past 30 days. The figure suggests a decline from $1.22 per share reported in the year-ago period.Notably, the company has a trailing four-quarter earnings surprise of 19.3%, on average. In the last reported quarter, this Cincinnati, OH-based company’s bottom line surpassed the Zacks Consensus Estimate by 17.4%.\nKey Factors to Note\nKroger is likely to have faced tough year-over-year comparisons in sales, as COVID-19 benefits are lapped. Industry experts believe that lower at-home consumption activities and a drop in pantry-loading trends might have hurt the company’s first-quarter top-line performance.Apart from this, stiff competition in the grocery segment remained a significant headwind. Again, costs related to additional employee payments and benefits, and investments undertaken to preserve safety and health of customers and team members amid the coronavirus crisis might have weighed on the to-be-reported quarter’s margins.While aforementioned factors do raise concerns, we cannot ignore the efforts undertaken by Kroger to strengthen position not only with respect to products but also in terms of the way consumers prefer shopping. The company has been making significant investments to enhance product freshness and quality, and expand digital capabilities. Impressively, Kroger has been introducing new items under its “Our Brands” portfolio. Cumulatively, these are likely to have aided the company’s first-quarter performance.The company’s “Restock Kroger” program involving investments in omni-channel platform, identifying margin-rich alternative profit streams, merchandise optimization, and lowering of expenses have been gaining traction. Realizing the need of the hour, the company has been offering a no-contact delivery option, low-contact pickup service and ship-to-home orders.\n\nThe Kroger Co. Price, Consensus and EPS Surprise\n \nThe Kroger Co. price-consensus-eps-surprise-chart | The Kroger Co. Quote\n\nWhat the Zacks Model Unveils\nOur proven model does not conclusively predict a beat for Kroger this earnings season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Kroger has a Zacks Rank #3 but an Earnings ESP of 0.00%.\nStocks With Favorable Combination\nHere are some companies you may want to consider as our model shows that these have the right combination of elements to post an earnings beat:\nKB Home KBH has an Earnings ESP of +1.87% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.General Mills GIS has an Earnings ESP of +2.06% and a Zacks Rank #3.Darden Restaurants DRI has an Earnings ESP of +17.46% and a Zacks Rank #3.\nBitcoin, Like the Internet Itself, Could Change Everything\nBlockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.See 3 crypto-related stocks now >>\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n \n\nGeneral Mills, Inc. (GIS) : Free Stock Analysis Report\n \n\nDarden Restaurants, Inc. (DRI) : Free Stock Analysis Report\n \n\nThe Kroger Co. (KR) : Free Stock Analysis Report\n \n\nKB Home (KBH) : Free Stock Analysis Report\n \n\nTo read this article on Zacks.com click here.\n \n\nZacks Investment Research","news_type":1},"isVote":1,"tweetType":1,"viewCount":81,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
